Boston Scientific Falls Short of Projected $150M in Q207

July 20, 2007 – Despite forecasts by analysts at Thomson Financial that Boston Scientific Corp. would earn $150 million in the second quarter of this year, the company came up short at $115 million in the second quarter, or 7.7 cents a share, due to a significant sales slump in implantable defibrillators and coronary stents.

In 2006, Boston Scientific reported a $4.3 billion loss from its April 2006 purchase of Guidant Corp. Excluding special charges related to the acquisition, the company's profit fell 56 percent from the second quarter of 2006.